The partnership, formalised in October 2025, reflects both organisations’ commitment to shaping the future of cancer care and personalised medicine.
Cyclowest will deliver research radiochemistry services for Phase I and early phase trials at Icon’s first-of-its-kind dedicated Theranostics and Molecular Imaging centre, opening in November at Hollywood Medical Centre, Nedlands, Perth, Western Australia.
Group Chief Medical Officer, Dr Ian Irving shared his enthusiasm for the partnership.
“The collaboration between Cyclowest and Icon represents a major milestone for theranostics in Australia,” said Dr Irving.
“By combining our strengths, we’re able to accelerate research, improve clinical outcomes, and offer patients access to the latest advancements in personalised medicine.
“We look forward to working closely with Cyclowest to set new standards in patient care and innovation.”
Through this collaboration, Cyclowest’s experts will support the development of new diagnostic and therapeutic radiopharmaceuticals for pharma-sponsored early phase theranostics cancer trials in Western Australia.
With a shared vision for advancing cancer care, Icon and Cyclowest are set to deliver meaningful change for patients, clinicians, and the broader healthcare community.
The partnership follows Icon’s continued investment in the latest treatments, techniques and personalised medicines
Icon Group is Australia’s largest dedicated cancer care provider and has expanded globally into New Zealand, Asia and the United Kingdom.
People from across Icon Group share their stories of success, career progression and being iconic.
At Icon, you’ll help change lives, every single day. In return for your passion, dedication and agility, we offer a workplace where you can.
Read the latest news and updates across Icon Group.